Crédits

5

Responsables William Jacot

Marie-Alix Poul

Planning planning HMBS310
Intervenants PU/MCU-Praticiens hospitaliers :

N. Houédé,  F Barlési,  A. Evrard, C Bourgier, D. Azria

PH chargés d’enseignement :

W. Jacot, D. Tosi, J. Ciccolini,

Enseignants chercheurs :

M.A. Poul, F. Mennechet, F. Gattacceca, F. Bernex, J. Ciccolini,

Chercheurs :

S. Roche, C Gongora, JM Pascussi,  V. Dardalhon, L. Gros, L. Le Cam, M. Busson, A Constantinou

Industriels :

H Bouchard, N. Guilbaud

Objectifs

The goal of this course is to provide a broad understanding of the various aspects of cancer cells sensitivity / resistance to cancer treatments, from the molecular targets of anticancer agents, targeting the cancer cells themselves or cancer microenvironment, to the individual modulation of cancer drugs response and toxicities. The course will review chemotherapy, targeted therapies,  immunotherapy and radiotherapy approaches in cancer. In addition, during the Pre‐clinical models practical sessions, experienced experts of the field will illustrate how human cancer can be modeled in the mouse, showing the latest technological developments based on genetically engineered mouse models as well as humanized primary xenograft models.

Description

Format: Conférences  30 h ; session pratique 10 h

Part I : Clinical basis of cancer therapy (3 h)
• Pivotal role of anatomapathology in diagnosis and prognosis of cancer
• Clinical trial methodology in cancerology

Part II : Chemotherapy, hormonotherapy and targeted therapies (10 h)
• Basis and principles of chemotherapy
• Targeted therapy : from hormonotherapy to small molecules inhibitors of tyrosine kinase
• Pharmacodynamics aspects (targets, signal transduction pathways) of drug resistance
• Pharmacogenomics and pharmacokinetics determinants of drug response and toxicity
• Cancer stem cells and drug response
• Improving drug delivery to the tumor: nanoparticles and tumor targeting

Part III : Immunotherapy (9 h)
• Immune response against cancer and tumor microenvironnement
• Antibody based‐immunotherapy against cancer, nanobodies
• NK and T‐cell based cancer immunotherapy
• Dendritic cells and anti‐cancer vaccination
• Antibody Drug Conjugates (ADC), the best of two world ?

Part IV : Radiobiology and radiotherapy (7 h)
• Radiobiology : physics and chemistry of radiation absorption, modes of cell death and cell‐survival curves
• Radiobiology : DNA damage, DNA repair, Cell signaling
• Radiobiology: time, dose, fractionation, repopulation, angiogenesis
• Radiosensitizers and radioprotector
• Biomarkers of hyper‐radiosensitive patients

Part V : Perspectives
• Strategies for new anticancer drug discovery and hit identification
• Clinical assessment and implication of biomarkers identification: from early targeted clinical treatment to daily practice

Part VI : Methodoloy in Cancer Research (8 h)
• Genetically engineered mouse models of human cancers and Humanized models
• Training session on small animal imaging (SPECT‐CT, Bioluminescence)
• Training session on anatomo‐pathological analyses of mouse models

Prérequis Basis in cell physiopathology
Modalités de contrôle des connaissances
1ère session Ecrit Oral TD CC
  100%  

 

2ème session : ecrit